Higher margins and new drugs help GlaxoSmithKline beat forecasts

LONDON (Reuters) - Improving margins in consumer health and growing demand for new drugs lifted GlaxoSmithKline's underlying earnings a better-than-expected 14 percent in the first quarter, keeping it on course to achieve a promised return to growth in 2016.